Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PolyNovo Limited (PNV.AX)
AUD1.00
-0.02 (-1.96%)
AU ASX Healthcare Medical - Devices
Address
320 Lorimer Street 3207
Port Melbourne, VIC, AU
Port Melbourne, VIC, AU
CEO
Bruce Peatey
Website
polynovo.com
IPO
1998-11-29
ISIN AU000000PNV0
Also trades on
Australian Securities Exchange · PNV.AX (AUD)
Other OTC · CALZF (USD)
Description
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD1.00
-0.02 (-1.96%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.33
Float Shares
614.67M
Free Float %
89.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.79% | +7.02% | +22.00% | +26.42% | -0.81% | -0.81% | -3.17% | -18.12% | -54.98% | +343.64% | +1,255.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.00
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
14.20
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+23.3% ★ Q4'25: +48.9% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+152.0% ★ Q4'25: -100.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+7.1% Q4'25: -2.3% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+6.1% Q4'25: +2.8% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+11.6% ★ Q4'25: +5.6% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-0.2% ★ Q4'25: -0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.64× ★ Q4'25: 2.36× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2003 actual |
Jun 2004 actual |
Jun 2007 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 8 Rev. Ana. 5 EPS Ana. |
Jun 2027 8 Rev. Ana. 5 EPS Ana. |
Jun 2028 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 20.30M (-100.0%)
|
836.00
est: 2.13M (-100.0%)
|
4.4K
est: 16.24M (-100.0%)
|
3.28M
est: 3.40M (-3.6%)
|
3.62M
est: 5.90M (-38.6%)
|
6.55M
est: 3.20M (+104.8%)
|
14.04M
est: 12.12M (+15.9%)
|
22.16M
est: 22.49M (-1.5%)
|
29.16M
est: 29.65M (-1.7%)
|
41.44M
est: 40.11M (+3.3%)
|
65.24M
est: 65.68M (-0.7%)
|
103.19M
est: 104.80M (-1.5%)
|
127.24M
est: 118.60M (+7.3%)
|
150.68M
146.79M – 160.67M
+27.0% YoY
|
183.09M
168.24M – 196.21M
+21.5% YoY
|
223.36M
220.82M – 225.89M
+22.0% YoY
|
| EBITDA |
-8.48M
est: -64.5K (-13,050.0%)
|
-12.20M
est: -6.6K (-183,713.1%)
|
-13.66M
est: -50.6K (-26,928.0%)
|
-4.15M
est: -10.8K (-38,432.2%)
|
-5.59M
est: -6.12M (+8.7%)
|
-6.91M
est: -10.1K (-67,989.5%)
|
-4.25M
est: -10.19M (+58.2%)
|
-3.27M
est: -5.27M (+37.9%)
|
-3.41M
est: -7.54M (+54.8%)
|
658.2K
est: -11.79M (+105.6%)
|
-2.71M
est: -18.53M (+85.4%)
|
4.59M
est: -29.84M (+115.4%)
|
10.45M
est: -375.3K (+2,885.0%)
|
-478.5K
-510.2K – -466.2K
-27.5% YoY
|
-581.4K
-623.1K – -534.3K
-21.5% YoY
|
-709.3K
-717.3K – -701.2K
-22.0% YoY
|
| EBIT |
-9.10M
est: -668.9K (-1,260.2%)
|
-12.36M
est: -68.8K (-17,854.0%)
|
-13.96M
est: -524.6K (-2,561.8%)
|
-4.10M
est: -111.8K (-3,565.3%)
|
-5.98M
est: -6.66M (+10.2%)
|
-6.81M
est: -105.3K (-6,373.8%)
|
-4.56M
est: -11.02M (+58.6%)
|
-4.11M
est: -6.54M (+37.2%)
|
-4.33M
est: -7.33M (+41.0%)
|
-931.0K
est: -11.46M (+91.9%)
|
-4.75M
est: -18.01M (+73.6%)
|
1.85M
est: -29.00M (+106.4%)
|
7.76M
est: -3.89M (+299.1%)
|
-4.96M
-5.29M – -4.84M
-27.5% YoY
|
-6.03M
-6.47M – -5.54M
-21.5% YoY
|
-7.36M
-7.44M – -7.28M
-22.0% YoY
|
| Net Income |
-8.57M
est: -33.19M (+74.2%)
|
-9.54M
est: -31.22M (+69.4%)
|
-13.41M
est: -36.90M (+63.7%)
|
-3.06M
est: -5.58M (+45.1%)
|
-5.01M
est: -6.12M (+18.3%)
|
-5.97M
est: -6.09M (+1.9%)
|
-3.19M
est: -10.60M (+69.9%)
|
-4.19M
est: -5.91M (+29.0%)
|
-4.61M
est: -7.56M (+39.1%)
|
-1.19M
est: -11.81M (+89.9%)
|
-4.93M
est: -4.92M (0.0%)
|
5.26M
est: 5.26M (+0.0%)
|
13.21M
est: 13.21M (+0.0%)
|
7.01M
3.43M – 8.79M
-46.9% YoY
|
16.35M
14.49M – 18.22M
+133.2% YoY
|
33.33M
23.26M – 34.88M
+103.8% YoY
|
| SGA |
1.14M
est: 15.93M (-92.8%)
|
778.6K
est: 1.64M (-52.5%)
|
4.43M
est: 12.49M (-64.5%)
|
4.66M
est: 2.66M (+75.1%)
|
6.15M
est: 4.63M (+32.8%)
|
7.97M
est: 2.51M (+217.3%)
|
12.13M
est: 9.51M (+27.5%)
|
20.37M
est: 17.65M (+15.4%)
|
24.86M
est: 23.27M (+6.8%)
|
29.84M
est: 31.47M (-5.2%)
|
53.20M
est: 51.54M (+3.2%)
|
78.55M
est: 82.24M (-4.5%)
|
98.56M
est: 93.07M (+5.9%)
|
118.24M
115.19M – 126.09M
+27.0% YoY
|
143.68M
132.03M – 153.97M
+21.5% YoY
|
175.28M
173.29M – 177.27M
+22.0% YoY
|
| EPS |
-0.37
est: -0.05 (-679.4%)
|
-0.04
est: -0.04 (+0.5%)
|
-0.05
est: -0.05 (+13.0%)
|
-0.01
est: -0.01 (+22.5%)
|
-0.01
est: -0.01 (+1.1%)
|
-0.01
est: -0.01 (-5.6%)
|
0.00
est: 0.00 (-2.8%)
|
-0.01
est: 0.00 (-50.0%)
|
-0.01
est: -0.01 (-22.6%)
|
0.00
est: 0.00 (-203.0%)
|
-0.01
est: -0.01 (+38.8%)
|
0.01
est: 0.01 (+5.0%)
|
0.02
est: 0.01 (+141.0%)
|
0.01
0.00 – 0.01
-7.3% YoY
|
0.02
0.02 – 0.03
+215.9% YoY
|
0.04
0.03 – 0.05
+70.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
32.00M
OE per share TTM
0.05
Owner's Yield
3.80%
Maintenance CapEx ratio
82,647.75%
Maint CapEx / Avg PPE
36.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 28 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares S&P/ASX Small Ordinaries ETF ISO.AX | 0.25% | 217.0K | 0.55% |
| 2 | iShares Ageing Population UCITS ETF AGED.L | 0.04% | 355.3K | 0.40% |
| 3 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 284.8K | 0.40% |
| 4 | Vanguard Australian Shares Index ETF VAS.AX | 0.03% | 5.33M | 0.07% |
| 5 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 978.4K | 0.06% |
| 6 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.98M | 0.06% |
| 7 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 39.9K | 0.30% |
| 8 | Vanguard FTSE Pacific ETF VPL | 0.00% | 585.2K | 0.07% |
| 9 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 9.4K | 0.22% |
| 10 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 1.22M | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
26.6K
Shares Outstanding
690.84M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bruce Peatey | Chief Executive Officer | 756.2K | male |
| Jan-Marcel Gielen | Chief Financial Officer & Company Secretary | 387.7K | male |
| Ahmed Hassan | Chief Manufacturing & Supply Chain Officer | — | male |
| Amy Demediuk | Company Secretary & General Counsel | — | female |
| Edward Graubart | President of North America | — | male |
| Kimberley Axon | Chief People Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PNV.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
